Pharmacological treatment of Insomnia

Current Clinical Neurology

Volumn , Issue , 2010, Pages 297-316

  Schweitzer, Paula K ^a   Curry, Denise Troy ^a   Eisenstein, Rhody D ^a   Walsh, James K ^a  

^a NONE

Author keywords

Antidepressants; Benzodiazepine receptor agonists; Insomnia; Melatonin; Melatonin receptor agonists; Pharmacotherapy; Valerian

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLONAZEPAM; DIPHENHYDRAMINE; DOXEPIN; ESCITALOPRAM; ESTAZOLAM; ESZOPICLONE; FLUOXETINE; FLURAZEPAM; LORAZEPAM; MELATONIN; MIRTAZAPINE; OLANZAPINE; PLACEBO; QUAZEPAM; QUETIAPINE; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRIMIPRAMINE; UNINDEXED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM;

AMNESIA; ANTEROGRADE AMNESIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; CHRONIC PAIN; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MISUSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERANCE; FALLING; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEADACHE; HEART ARRHYTHMIA; HEART CONDUCTION; HISTORY OF MEDICINE; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; INJURY; INSOMNIA; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANIC; PATIENT MONITORING; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PRIAPISM; PRIORITY JOURNAL; QUALITY OF LIFE; REBOUND; REMISSION; RHEUMATOID ARTHRITIS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; URINE RETENTION; WEAKNESS; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 78649362354     PISSN: 15590585     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-042-7_23     Document Type: Article

References (121)

1. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. (2005) Sleep 28:1049-1057
2. Walsh JK, Schweitzer PK (1999) Ten-year trends in the pharmacological treatment of insomnia. Sleep 22:371-375
3. Walsh JK (2004) Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 27(8):1441-1442
4. National Institute of Mental Health (1984) Consensus conference report: drugs and insomnia-the use of medication to promote sleep. JAMA 251:2410-2414
5. Mendelson WB, Roth T, Cassella J, Roehrs T, Walsh JK, Woods JH et al (2004) The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit (NCDEU) meeting symposium. Sleep Med Rev 8:7-17
6. McCall WV (2002) Pharmacologic treatment of insomnia. In: Lee-Chiong TL Jr, Sateia MJ, Carskadon MA (eds) Sleep Medicine. Hanley & Belfus, Inc., Philadelphia, PA, pp 169-176
7. Roehrs T, Roth T (2003) Hypnotics: An update. Current Neurol Neurosci Rep 3:181-184
8. Ohayon MM (1997) Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiat Res 31:333-346
9. Buysse DJ, Reynolds CF III, Kupfer DJ, Thorpy MJ, Bixler E, Manfredi R et al (1994) Clinical diagnoses in 216 insomnia patients using the international classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV field trial. Sleep 17:630-637
10. Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46:53-58
11. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997) Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42: 209-212
12. Agargun MY, Kara H, Solmaz M (1997) Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatr 58:249-251
13. Hall RC, Platt DE (1999) Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics 40:18-27
14. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MG (1997) Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 146:105-114
15. Breslau N, Roth T, Rosenthal L, Andreski P (1996) Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 39:411-418
16. Walsh JK (2008) What medications are used to treat insomnia. Paper presented at Development of Hypnotic Agents, Sleep Research Society, New York, 3-4 April 2008
17. Roehrs T, Hollebeek E, Drake C, Roth T (2002) Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 53:571-576
18. S (2008) Stahl's essential psychopharmacology: neuroscientific basis and practical applications, 3rd edn. Cambridge University Press, New York
19. Nowell PD, Mazumdar S, Buysse DJ et al (1997) Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278:2170-2177
20. Holbrook AM, Crowther R, Lotter A, Cheng C, King D (2000) Meta-analysis of benzodiazepine use in the treatment of insomnia. Canadian Medical Association Journal 162(2):225-233
21. Walsh JK, Pollack CP, Scharf MB, Schweitzer PK, Vogel GW (2000) Lack of residual sedation following middle of the night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23(1):17-21
22. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26(7):793-799
23. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T (2007) Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 30(8):959-968
24. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6(6):487-495
25. Scharf MB, Roth T, Vogel GW, Walsh JK (1994) J Clin Psychiatry 55(5):192-199
26. Walsh JK, Vogel GW, Scharf M, Erman M, William EC, Schweitzer PK et al (2000) A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1(1):41-49
27. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS (2005) Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 6(2):107-113
28. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK (2000) Eight weeks of non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Sleep 23(8):1087-1096
29. Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65(8):1128-1137
30. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T (2008) ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallelgroup, multicenter study. Sleep 31:79-90
31. Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK (1999) Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60(10):68-76
32. Fava M, Asnis G, Shrivastaava R, Lydiard RB, Bastani B, Sheehan D, Roth T (2008) Improved insomnia symptoms and daily functioning in patients wieth comorbid major depressive disorder and insomnia following zolpidem estendedrelease 12.5 mg and escitalopram co-treatment. Sleep 31:A324
33. Sheehan D, Asnis G, Shrivastava R, Lydiard RB, Bastani B, Roth T (2008) Zolpidem estended-release 12.5 mg co-adiministered with escitalopram improves insomnia symptoms and next-day functioning in generalized anxiety disorder comorbid with chronic insomnia. Sleep 31, A325
34. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59(11):1052-1060
35. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and generalized anxiety disorder. Arch Gen Psychiatry 65(5):551-562
36. Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK (1996) Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 23(2):245-252
37. Doghramji K, Browman CP, Gaddy JR, Walsh JK (1991) Triazolam diminishes daytime sleepiness and sleep fragmentation in patients with periodic limb movements in sleep. J Clin Psychopharmacol 11(5):284-290
38. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S (2003) Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood, and quality of life. Psychol Med 33(7):1223-1237
39. McAndrews PM, Weiss RT, Sandor P, Taylor A, Carlen PL, Shapiro CM (2003) Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 18(1):51-57
40. Blin O, Micallef-Roll J, Audebert C et al (2006) A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 26:284-289
41. Fairweather DB, Kerr JK, Hindmarch I (1992) The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eru J Clin Pharmacol 43:597-601
42. Berlin I, Warot D, Hergueta T et al (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100-106
43. Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8(4):309-325
44. Kelly KD, Pickett W, Yiannakoulias N, Rowe BH, Schopflocher DP, Svenson L, Voaklander DC (2003) Medication use and falls in community-dwelling older persons. Age Ageing 32(5):503-509
45. Brassington GS, King AC, Bliwise DL (2000) Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 48(10):1234-1240
46. Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD (2005) Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53(6):955-962
47. Roth T, Roehrs TA, Stepanski EJ et al (1990) Hypnotics and behavior. Am J Med 8:43S-46S
48. Greenblatt D, Harmatz JS, Shapiro L et al (1991) Sensitivity to triazolam in elderly. N Engl J Med 324:1691-1698
49. Buffett-Jerrott SE, Stewart SH (2002) Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8(1):45-58
50. Roehrs T, Merlotti L, Zorick F, Roth T (1992) Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology (Berl) 108(1-2):67-71
51. Griffiths RR, Roache JD (1985) Abuse liability of benzodiazepines: a review of human studies evaluating subjective and/or reinforcing effects. In: Smith DE, Wesson DR (eds) The benzodiazepines: current standards for medical practice. MTP, Hingman, MA, pp 209-225
52. Balter MB, Uhlenhuth EH (1991) The beneficial and adverse effects of hypnotics. J Clin Psychiatry 52(7, suppl):16-23
53. Roehrs T, Bonahoom A, Pedrosi B et al (2002) Nighttime versus daytime hypnotic self-administration. Psychopharmacology 161:137-142
54. Roehrs T, Pedrosi B, Rosenthal L, Roth T (1996) Hypnotic self administration and dose escalation. Psychopharmacology (Berl) 127(2):150-154
55. Roehrs T, Bonahoom A, Pedrosi B et al (2002) Disturbed sleep predicts hypnotic self administration. Sleep Med 3:61-66
56. Ladewig D (1983) Abuse of benzodiazepines in western European society-incidence and prevalence, motives, drug acquisition. Pharmacopsychiatria 16(4):103-106
57. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48(2):301-310
58. Erman M, Seiden D, Zammit G, Sainati S, Zheng J (2006) An efficacy, safety and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 7:17-24
59. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T (2007) Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 3:495-504
60. Roth T, Seiden D, Sainati S, Wand-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine 7(Wang-Weigand S, J):312-318
61. Roth T, Seiden D, Wang-Weigand S, Zhang J (2007) A 2-night, 3-period crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23:1005-1014
62. DeMicco M, Wang-Eeigand S, Zhang J (2006) Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1 year study. Sleep 29 (suppl):A234
63. Richardson G, Zammit G, Rodriguez L, Zhang J (2005) Evaluation of circadian phase-shifting effects of ramelteon in healthy subjects. In: Proceedings of international congress of applied chronobiology & chronomedicine, Antalya, Turkey, 1-5 June 2005
64. Borja NL, Daniel KL (2006) Ramelteon for the treatment of insomnia. Clin Ther 28:1540-1555
65. Johnson MW, Suess P, Ramelteon GR (2006) A novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 63:1149-1157
66. Brogden RN, Heel RC, Speight TM, Avery GS (1981) Trazodone: a review of its pharmacologic properties and therapeutic use in depression and anxiety. Drugs 21:401-429
67. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223-229
68. A (1997) Pharmacology of antidepressants. J Clin Psychopharmacol 17(Suppl 1):2S-18S
69. Preskorn SH (1993) Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 54(Suppl):14-34
70. Richelson E (1994) The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 55(Suppl A):34-39
71. De Boer T (1996) The pharmacological profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19-25
72. Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O'Hanlon JF (2000) Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20(5):531-537
73. Sharpley AL, Cowen PJ (1995) Effects of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37:85-98
74. Mendelson WB (2005) A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 66:469-476
75. Walsh JK, Erman M, Erwin CW, Jamieson A, Mahowald M, Regestein Q et al (1998) Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13:191-198
76. Montgomery I, Oswald I, Morgan K, Adam K (1983) Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16: 139-144
77. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C (2004) The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 5:15-20
78. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Ruther E et al (2002) Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 35:165-174
79. Hohagen F, Montero RF, Weiss E, Lis S, Schonbrunn E, Dressing H et al (1994) Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 244(2):65-72
80. Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F et al (2001) Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62:453-463
81. Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30:1555-1561
82. Roth T, Durrence H, Gotfried M, Hull S, Corser B, Scharf M, Orr W, Buddharaju V, Schwaretz H, Jochelson P (2008) Efficacy and safety of doxepin 1 and 3 mg in a 3-month trial of elderly adults with chronic primary insomnia. Sleep 31:A230
83. Gillin JC, Wyatt RJ, Fram D, Snyder F (1978) The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacol (Berl) 59:267-272
84. Hartmann E, Cravens J (1973) The effects of long-term administration of psychotropic drugs on human sleep: III. The effects of amitriptyline. Psychopharmacologia 33:185-202
85. Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, Weikel JC, Sonntag A, Steiger A (2006) Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine. Neuropsychopharmacology 31:832-844
86. Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations: tricyclic antidepressants vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand 101(Suppl 403):17-25
87. Mir S, Taylor D (1997) The adverse effects of antidepressants [mood disorders]. Curr Opin Psychiatry 10(2):88-94
88. Haria M, Fitton A, McTavish D (1994) Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4:331-355
89. Golden RN, Dawkins K, Nicholas L (2004) Trazodone and nefazodone. In: Schatzberg A, Nemeroff CB (eds) The American Psychiatric Publishing Textbook of Psychopharmcaology. American Psychiatric Publishing, Washington DC, pp 315-325
90. Metz A, Shader RI (1990) Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 5:191-194
91. Sakulsripong M, Curran HV, Lader M (1991) Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 40:43-48
92. Wiegand M, Landry T, Bruckner T, Pohl C, Zdenko V, Jahn T (2008) Quetiapine in primary insomnia: a pilot study. Psychopharmacology 196:337-338
93. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T (2005) Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial. Clin Neuropharmacol 28(4):185-187
94. Estivill E, de la Fuente V, Segarra F, Albares J (2004) The use of olanzapine in sleep disorders. An open trial with nine patients. Rev Neurol 38(9):829-831
95. Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R (1983) Diphenhydramine in insomniac family practice patients: a double- blind study. J Clin Pharmacol 23(5-6):234-242
96. Glass JR, Sproule BA, Herrmann N, Busto UE (2008) Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 28:182-188
97. Schweitzer PK, Muehlbach MJ, Walsh JK (1994) Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immuno 94:716-724
98. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T (2002) Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 22:511-515
99. Basu R, Dodge H, Stoehr GP, Ganguli M (2003) Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J geriatric Psychiatry 11:205-213
100. Hughes RJ, Badia P (1997) Sleep-promoting and hypothermic effects of daytime melatonin administration in human. Sleep 20:124-131
101. Dollins AB, Zhadnova IV, Wurtman RJ, Lynch HJ, Deng MH (1994) Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 91(5):1824-1828
102. James SP, Mendelson WB, Sack DA, Rosenthal NE, Wehr TA (1987) The effect of melatonin on normal sleep. Neuropsychopharmacology 1:41-44
103. James SP, Sack DA, Rosenthal NE, Mendelson WB (1990) Melatonin administration in insomnia. Neuropsychopharmacology 3(1):19-23
104. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL (1991) The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 20:371-376
105. Lemoine P, Nir T, Laudon M, Zisapel N (2007) Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16:372-380
106. Buscemi N, Vandermeer B, Hooton N et al (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20:1151-1158
107. Brzezinski A, Vangel MG, Wurtman RJ et al (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41-50
108. Rogers NL, Kennaway DJ, Dawson D (2003) Neurobehavioral performance effects of daytime melatonin and temazepam administration. J Sleep Res 12:207-212
109. Lusardi P, Preti P, Savino S, Piazza E, Zoppi A, Fogari R (1997) Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 2(2):99-103
110. Lusardi P, Piazza E, Fogari R (2000) Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 49(5):423-427
111. Naylor S, Johnson KL, Williamson BL, Klarskov K, Gleich GJ (1999) Structural characterization of contaminants in commercial preparations of melatonin by online HPLC-electrospray ionization-tandem mass spectrometry. Adv Exp Med Biol 467:769-777
112. Bliwise DL, Ansari FP (2007) Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 30(7):881-884
113. Houighton PJ (1999) The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 51:505-512
114. Krystal AD, Ressler I (2001) The use of valerian in neuropsychiatry. CNS Spectr 6:841-847
115. Balderer G, Borbely AA (1985) Effect of valerian on human sleep. Psychopharmacology (Berl) 87(4):406-409
116. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I (2000) Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33(2):47-53
117. Schulz H, Stolz C, Muller J (1994) The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 27(4):147-151
118. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V (2005) Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebocontrolled clinical trial. Sleep 28(11):1465-1471
119. Stevinson C, Ernst E (2000) Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 1(2):91-99
120. Taibi DM, Landis CA, Petry H, Vitiello MV (2007) A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 11(3):209-230
121. Chouinard G, Lefko-Singh K, Teboul E (1999) Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 19(4):533-552